ACADIA Pharmaceuticals (ACAD) Stock: Gains On Clinical Data
After releasing positive clinical data, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is making a run for the top in the market this morning. The data came from the company’s Phase 2 CLARITY study, assessing pimavanserin as an option for patients with MDD. With the positive data in mind, excited investors are pushing the stock upward. Today, we’ll … Read more